DermTech (OTCPK:DMTK.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

DMTK.Q Stoklara Genel Bakış

Bir moleküler tanı şirketi olan DermTech, Inc. Amerika Birleşik Devletleri'nde melanom tanısı ve yönetimine yardımcı olmak için yeni non-invaziv genomik testlerin geliştirilmesi ve pazarlanmasıyla uğraşmaktadır.

Şirket hakkında

DMTK.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Risk Analizi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $4K )

Kazançlar son 5 yılda yılda 36.7% oranında azaldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 1 daha fazla risk

DermTech, Inc. Rakipler

Comera Life Sciences Holdings

OTCPK:CMRA

US$3.1k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Aridis Pharmaceuticals

OTCPK:ARDS

US$10.7k

ObsEva

OTCPK:OBSE.F

US$11.7k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti DermTech
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0001
52 Haftanın En Yüksek Seviyesi	US$1.99
52 Haftanın En Düşük Seviyesi	US$0.0001
Beta	2.27
11 Aylık Değişim	-99.00%
3 Aylık Değişim	-99.78%
1 Yıllık Değişim	-99.99%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

Hissedar Getirileri

	DMTK.Q	US Biotechs	US Pazar
7D	0%	-0.4%	-1.2%
1Y	-100.0%	20.1%	30.6%

Getiri vs. Endüstri: DMTK.Q geçen yıl % 20.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: DMTK.Q geçen yıl % 30.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is DMTK.Q's price volatile compared to industry and market?
DMTK.Q volatility
DMTK.Q Average Weekly Movement	1,030.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: DMTK.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: DMTK.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 523% dan 1031% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	207	Bret Christensen	www.dermtech.com

Bir moleküler tanı şirketi olan DermTech, Inc. Amerika Birleşik Devletleri'nde melanomun tanı ve yönetimine yardımcı olmak için yeni non-invaziv genomik testlerin geliştirilmesi ve pazarlanmasıyla uğraşmaktadır. Şirket, melanom dışı cilt kanserleri için ürün geliştirmeye yönelik melanom tespitini artırmanın yenilikçi bir non-invaziv yolu olan DermTech Melanom Testi (DMT) sunmaktadır. Ayrıca, şüpheli lezyonlara biyopsi yapmak için neşter kullanarak standart bakım da dahil olmak üzere cilt örneği toplamak için invazif olmayan bir yol sağlayan DermTech Smart Sticker'ı da sunmaktadır.

DermTech, Inc. Temel Bilgiler Özeti

DermTech'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DMTK.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$3.53k
Kazançlar(TTM)	-US$89.63m
Gelir(TTM)	US$15.66m

0.0x

P/S Oranı

0.0x

F/K Oranı

DMTK.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DMTK.Q gelir tablosu (TTM)
Gelir	US$15.66m
Gelir Maliyeti	US$14.33m
Brüt Kâr	US$1.33m
Diğer Giderler	US$90.96m
Kazançlar	-US$89.63m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.54
Brüt Marj	8.51%
Net Kâr Marjı	-572.19%
Borç/Özkaynak Oranı	0%

DMTK.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DMTK.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

DermTech, Inc. Rakipler

OTCPK:CMRA

US$3.1k

OTCPK:GNCA.Q

US$5.9k

OTCPK:ARDS

US$10.7k

OTCPK:OBSE.F

US$11.7k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022